Characteristic | Local control | Progression free survival | Overall survival | |||
---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
SBRT total dose | 1.05 (0.98–1.19) | 0.15 | 0.97 (0.90–1.05) | 0.51 | 1.03 (0.97–1.10) | 0.3 |
SBRT BED10 | 1.02 (0.99–1.05) | 0.13 | 0.99 (0.95–1.03) | 0.53 | 1.02 (0.97–1.05) | 0.3 |
Metastatic or recurrent disease (reference = primary disease) | 1.63 (0.54–4.93) | 0.38 | 1.48 (0.39–5.61) | 0.56 | 0.78 (0.27–2.30) | 0.65 |
Re-irradiation (reference = no prior radiation) | 2.70 (0.92–7.92) | 0.07 | 0.56 (0.15–2.12) | 0.39 | 1.24 (0.41–3.72) | 0.7 |
Histology (reference = other) | ||||||
Adenocarcinoma | 0.63 (0.01–62.45) | 0.77 | 3.26 (0.03–337.09) | 0.61 | 0.75 (0.01–73.55) | 0.9 |
Squamous cell carcinoma | 1.78 (0.02–173.35) | 0.12 | 2.28 (0.02–238.09) | 0.72 | 0.72 (0.01–72.60) | 0.89 |
Tumor location (reference = lung parenchyma + hilum) | ||||||
Mediastinum | 1.02 (0.19–6.70) | 0.98 | 0.87 (0.15–5.23) | 0.88 | 1.40 (0.29–6.69) | 0.67 |
Hilum | 1.66 (0.37–9.99) | 0.55 | 1.80 (0.29–11.23) | 0.52 | 0.36 (0.07–1.98) | 0.24 |
Mediastinum + hilum | 1.64 (0.29–11.14) | 0.59 | 6.42 (0.25–167.81) | 0.26 | 0.91 (0.15–5.42) | 0.91 |
ITV | 1.00 (0.97–1.01) | 0.78 | 0.99 (0.99–1.00) | 0.11 | 1.00 (0.99–1.00) | 0.27 |
PTV | 1.00 (0.99–1.00) | 0.73 | 0.99 (0.99–1.00) | 0.1 | 1.00 (0.99–1.00) | 0.29 |
D98 | 1.03 (0.97–1.09) | 0.28 | 0.98 (0.92–1.07) | 0.74 | 1.03 (0.97–1.09) | 0.34 |
D99 | 1.03 (0.98–1.09) | 0.27 | 0.99 (0.91–1.07) | 0.78 | 1.02 (0.97–1.09) | 0.41 |
PET SUV max | 1.00 (0.90–1.12) | 0.98 | 0.99 (0.85–1.16) | 0.91 | 0.94 (0.80–1.09) | 0.4 |
Age | 0.99 (0.94–1.03) | 0.64 | 1.05 (0.99–1.12) | 0.12 | 0.99 (0.92–1.02) | 0.22 |
Sex (reference = female) | 1.75 (0.61–5.06) | 0.3 | 0.81 (0.21–3.07) | 0.76 | 2.06 (0.69–6.13) | 0.2 |